Vicrostatin - An anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Minea, Radu O ^a   Helchowski, Corey M ^a   Zidovetzki, Samuel J ^a   Costa, Fritz K ^a   Swenson, Stephen D ^a   Markland Jr , Francis S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANGIOGENESIS INHIBITOR; DISINTEGRIN; DNA FRAGMENT; INTEGRIN; MATRIGEL; UNCLASSIFIED DRUG; VICROSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIAPOPTOTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; DRUG ACTIVITY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; ENDOTHELIUM CELL; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIPOSOMAL DELIVERY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL LINE, TUMOR; DISINTEGRINS; HUMANS; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION;

ANIMALIA;

EID: 77955223245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010929     Document Type: Article

References (87)

1. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335.
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
3. Petrelli A, Valabrega G (2009) Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 10: 589-600.
4. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727.
5. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
6. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100.
7. Bissell MJ, Rizki A, Mian IS (2003) Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol 15: 753-762.
8. Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222: 124-138.
9. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, et al. (2009) An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15: 1163-1169.
10. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, et al. (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nature Medicine 8: 27-34.
11. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphavbeta3 integrin. Cancer Cell 3: 589-601.
12. Serini G, Valdembri D, Bussolino F (2006) Integrins and angiogenesis: a sticky business. Exp Cell Res 312: 651-658.
13. Mahabeleshwar GH, Chen J, Feng W, Somanath PR, Razorenova OV, et al. (2008) Integrin affinity modulation in angiogenesis. Cell Cycle 7: 335-347.
14. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
15. Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, et al. (2007) Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 25: 632-646.
16. Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE (2008) Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28: 1703-1713.
17. Bix G, Iozzo RV (2005) Matrix revolutions: ''tails'' of basement-membrane components with angiostatic functions. Trends Cell Biol 15: 52-60.
18. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, et al. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alphavbeta3 and alpha5beta1 integrins. Proc Natl Acad SciUSA 100: 4766-4771.
19. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, et al. (1990) Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 195: 168-171.
20. McLane MA, Joerger T, Mahmoud A (2008) Disintegrins in health and disease. Front Biosci 13: 6617-6637.
21. Huang TF, Yeh CH, Wu WB (2001) Viper venom components affecting angiogenesis. Haemostasis 31: 192-206.
22. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, et al. (2004) Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 3: 499-511.
23. Saudek V, Atkinson RA, Pelton JT (1991) Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 30: 7369-7372.
24. Moiseeva N, Bau R, Swenson SD, Markland FS, Jr., Choe JY, et al. (2008) Structure of acostatin, a dimeric disintegrin from Southern copperhead (Agkistrodon contortrix contortrix), at 1.7 A resolution. Acta Crystallogr D Biol Crystallogr 64: 466-470.
25. McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S (1998) Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 219: 109-119.
26. Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS (1994) Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res 73: 39-52.
27. Zhou Q, Nakada MT, Arnold C, Markland FS (1999) Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 3: 259-269.
28. Trikha M, De Clerck YA, Markland FS (1994) Contortrostatin, a snake venom disintegrin, inhibits beta1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res 54: 4993-4998.
29. Zhou Q, Nakada MT, Brooks PC, Swenson SD, Ritter MR, et al. (2000) Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. Biochem Biophys Res Commun 267: 350-355.
30. Minea R, Swenson S, Costa F, Chen TC, Markland FS (2005) Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb 34: 177-183.
31. Ribatti D (2009) Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 33: 638-644.
32. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, et al. (2002) Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62: 1944-1947.
33. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166: 97-109.
34. Ritter MR, Zhou Q, Markland FS, Jr. (2000) Contortrostatin, a snake venom disintegrin, induces alphavbeta3- mediated tyrosine phosphorylation of CAS and FAK in tumor cells. J Cell Biochem 79: 28-37.
35. Schmitmeier S, Markland FS, Schonthal AH, Chen TC (2005) Potent mimicry of fibronectin-induced intracellular signaling in glioma cells by the homodimeric snake venom disintegrin contortrostatin. Neurosurgery 57: 141-153; discussion 141-153.
36. Park SH, Raines RT (2004) Fluorescence polarization assay to quantify proteinprotein interactions. Methods Mol Biol 261: 161-166.
37. Osborne CK, Hobbs K, Clark GM (1985) Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice. Cancer Res 45: 584-590.
38. Protopapa E, Delides GS, Revesz L (1993) Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 29A: 1391-1393.
39. Fox SB, Harris AL (2004) Histological quantitation of tumour angiogenesis. Apmis 112: 413-430.
40. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, et al. (1993) A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (N Y) 11: 187-193.
41. Fujii Y, Okuda D, Fujimoto Z, Horii K, Morita T, et al. (2003) Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD. J Mol Biol 332: 1115-1122.
42. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, et al. (1999) Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. J Biol Chem 274: 37809-37814.
43. Carrington JC, Dougherty WG (1988) A viral cleavage site cassette: identification of amino acid sequences required for tobacco etch virus polyprotein processing. Proc Natl Acad SciUSA 85: 3391-3395.
44. Ritter MR, Markland FS, Jr. (2001) Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin. Toxicon 39: 283-289.
45. Artoni A, Li J, Mitchell B, Ruan J, Takagi J, et al. (2004) Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad SciUSA 101: 13114-13120.
46. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, et al. (1995) Antiintegrin alphavbeta3 blocks human breast cancer growth and angiogenesis in human skin. Journal of Clinical Investigation 96: 1815-1822.
47. Golubkov V, Hawes D, Markland FS (2003) Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis 6: 213-224.
48. Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and Metastasis of Human Breast Carcinoma Cell Lines in Nude Mice. Cancer Res 50: 717-721.
49. Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69: 5292-5293.
50. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB- 435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104: 13-19.
51. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802.
52. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40: 2-11.
53. Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, et al. (2009) Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18: 135-141.
54. Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1-18.
55. Contois L, Akalu A, Brooks PC (2009) Integrins as ''functional hubs'' in the regulation of pathological angiogenesis. Semin Cancer Biol 19: 318-328.
56. Ivaska J, Heino J (2009) Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res 339: 111-120.
57. Serini G, Napione L, Bussolino F (2008) Integrins team up with tyrosine kinase receptors and plexins to control angiogenesis. Curr Opin Hematol 15: 235-242.
58. Napione L, Cascone I, Mitola S, Serini G, Bussolino F (2007) Integrins: a flexible platform for endothelial vascular tyrosine kinase receptors. Autoimmun Rev 7: 18-22.
59. Geiger B, Spatz JP, Bershadsky AD (2009) Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 10: 21-33.
60. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111.
61. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV (2006) Integrin signaling is critical for pathological angiogenesis. J Exp Med 203: 2495-2507.
62. Tucker GC (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8: 96-103.
63. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nature Medicine 8: 918-921.
64. McCarty JH, Barry M, Crowley D, Bronson RT, Lacy-Hulbert A, et al. (2008) Genetic ablation of alphav integrins in epithelial cells of the eyelid skin and conjunctiva leads to squamous cell carcinoma. Am J Pathol 172: 1740-1747.
65. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, et al. (2005) Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad SciUSA 102: 2934-2939.
66. Clamp AR, Jayson GC (2005) The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 93: 967-972.
67. Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, et al. (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like proprotein convertases. Cancer Res 68: 6922-6931.
68. Serini G, Maione F, Giraudo E, Bussolino F (2009) Semaphorins and tumor angiogenesis. Angiogenesis 12: 187-193.
69. Eble JA (2010) Matrix biology meets toxinology. Matrix Biol 29: 239-247.
70. Juarez P, Comas I, Gonzalez-Candelas F, Calvete JJ (2008) Evolution of snake venom disintegrins by positive Darwinian selection. Mol Biol Evol 25: 2391-2407.
71. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, et al. (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254.
72. Barkan D, Green JE, Chambers AF (2010) Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46: 1181-1188.
73. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68: 6241-6250.
74. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, et al. (1999) N-Methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J Med Chem 42: 3033-3040.
75. Goodman SL, Holzemann G, Sulyok GA, Kessler H (2002) Nanomolar small molecule inhibitors for alphavbeta6, alphavbeta5, and alphavbeta3 integrins. J Med Chem 45: 1045-1051.
76. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, et al. (2007) Assessment of the biological and pharmacological effects of the alphavbeta3 and alphavbeta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18: 1400-1407.
77. Reardon DA, Nabors LB, Stupp R, Mikkelsen T (2008) Cilengitide: an integrintargeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17: 1225-1235.
78. Varner JA, Nakada MT, Jordan RE, Coller BS (1999) Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3: 53-60.
79. Nash GF, Turner LF, Scully MF, Kakkar AK (2002) Platelets and cancer. Lancet Oncol 3: 425-430.
80. Jurasz P, Alonso-Escolano D, Radomski MW (2004) Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143: 819-826.
81. Kim S, Harris M, Varner JA (2000) Regulation of integrin alphavbeta3- mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 275: 33920-33928.
82. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156: 1345-1362.
83. Carbonell WS, Ansorge O, Sibson N, Muschel R (2009) The vascular basement membrane as ''soil'' in brain metastasis. PLoS One 4: e5857.
84. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
85. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
86. Ellis LM, Reardon DA (2009) Cancer: The nuances of therapy. Nature 458: 290-292.
87. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, et al. (2000) Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 61: 249-260.